Life Sciences Research approved to list on NYSE

By Jennifer Chiou

New York, Aug. 22 - Life Sciences Research, Inc. announced the approval of its listing application for the New York Stock Exchange and it will begin trading on Sept. 7 under the ticker symbol "LSR."

In the meantime, the company will continue to trade on the Nasdaq over-the-counter bulletin board.

"The growing visibility LSR has enjoyed in the investment community has played an important part in our qualifying for the NYSE," said Andrew Baker, chairman and chief executive officer, said in a news release.

"We are confident that this listing will provide us with improved liquidity through access to a broader domestic and worldwide investor base."

Based in East Millstone, N.J., the company operates as a contract research organization that tests for pharmaceutical, biotechnology, agrochemical and industrial chemical companies through its subsidiaries.

The company's objective is to identify risks to humans, animals or the environment from the use or manufacture of chemicals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.